Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Chronic kidney disease in acute coronary syndromes: what is the real burden?
Session:
Painel 6 - Doença Coronária 13
Speaker:
Carolina Saleiro
Congress:
CPC 2020
Topic:
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme:
13. Acute Coronary Syndromes
Subtheme:
13.2 Acute Coronary Syndromes – Epidemiology, Prognosis, Outcome
Session Type:
Posters
FP Number:
---
Authors:
Carolina Saleiro; Diana Decampos; Rogerio Teixeira; João Lopes; Ana Rita M. Gomes; José Pedro Sousa; Luís Puga; Joana M. Ribeiro; Cândida Cristóvão; Carolina Lourenço; Marco Costa; Lino Gonçalves
Abstract
<p><strong>Background: </strong>Patients with chronic kidney disease (CKD) are at increased risk of composite cardiovascular (CV) events and all-cause mortality. However, current aggressiveness of therapeutic strategies may minimize the course of the disease.</p> <p><strong>Aim: </strong>To assess the prognostic impact of optimized medical treatment in a CKD population with acute coronary syndrome (ACS).</p> <p><strong>Methods: </strong>355 ACS patients admitted to a single coronary care with CKD who were discharged from hospital were included. Those with end-stage renal disease were excluded. Three groups were created based on the KDIGO classification: Group A (Stage 3A, eGFR [estimated glomerular filtration rate] 45-59mL/min/1.73 m2) N=190; Group B (Stage 3B, eGFR 30-44mL/min/1.73 m2) N=113; and Group C (Stage 3B, eGFR 15-29mL/min/1.73 m2) N= 52. The primary endpoint was long-term all-cause mortality. Kaplan-Meyer survival curves and Cox regression were done. The median of follow-up was 32 (IQ 15-70) months.</p> <p><strong>Results: </strong>Groups were similar regarding demographics, CV risk factors, ACS type, heart failure diagnosis, left ventricular (LV) systolic function, peak troponin, multivessel disease, treatment option (PCI, CABG or OMT) and medical therapy at discharge. More advance renal failure patients had a higher prevalence of diabetes mellitus (DM) (40% vs 50% vs 58%,<em> P< 0.05</em>); a lower haemoglobin (13±2 vs 12±2 vs 11±1 g/dL,<em> P<0.001</em>), a higher NT-proBNP (<em>P<0,001</em>) and were less likely to receive ACE inhibitors/angiotensin II antagonist at discharge (95% vs 92% vs 82%, <em>P<0.05</em>). 170 patients met the primary outcome. Kaplan-Meyer curves showed decreased survival with worse renal function (Group A 68% vs Group B 57% vs Group C 37%, Log Rank <em>P=0.006 – Figure 1</em>). After adjustment for age, DM, haemoglobin, NT-proBNP, LV systolic function and ACE inhibitors/angiotensin II antagonist at discharge, eGFR was not associated with increased death (HR 1.00, 95% CI 0.98-1.01). In this model, only age (HR 1.04, 95% CI 1.01-1.07), haemoglobin (HR 0.86, 95% CI 0.979-0.94), Nt-proBNP (HR 1.00, 95% CI 1.00-1.00) and impaired LV function (LV ejection fraction 40-49%: HR 2.95, 95% CI 1.89-4.81; LV ejection fraction <40%: HR 2.15, 95% CI 1.44-3.21) remained associated with the outcome.</p> <p><strong>Conclusion: </strong>The worse outcome attributed to CKD after an ACS seems to be related not the eGFR itself but to associated comorbidities such as age, anaemia, fluid overload and impaired LV function. The fact that some of these comorbidities may be altered by intensive therapy indicates that CKD patients should also be candidates to optimized medical treatment. </p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site